Q1 Earnings Estimate for Liquidia Issued By Lifesci Capital

Liquidia Co. (NASDAQ:LQDA - Free Report) - Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for shares of Liquidia in a research report issued to clients and investors on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Liquidia's current full-year earnings is ($1.51) per share.

Other equities research analysts have also recently issued reports about the company. Scotiabank increased their price target on Liquidia from $30.00 to $34.00 and gave the company a "sector outperform" rating in a research note on Thursday, March 20th. Needham & Company LLC upped their price objective on shares of Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th. Finally, Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of "Buy" and a consensus price target of $26.63.

Liquidia Trading Down 0.4 %

Shares of LQDA traded down $0.06 during midday trading on Friday, hitting $15.60. 676,229 shares of the company's stock traded hands, compared to its average volume of 933,973. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -9.57 and a beta of 0.07. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.92. The firm's fifty day moving average is $14.87 and its 200-day moving average is $12.27.

Remove Ads

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LQDA. Corebridge Financial Inc. lifted its stake in shares of Liquidia by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock valued at $371,000 after purchasing an additional 694 shares during the period. Catalina Capital Group LLC increased its holdings in Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock valued at $215,000 after buying an additional 1,125 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after acquiring an additional 1,277 shares during the period. Summit Investment Advisors Inc. boosted its stake in shares of Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after acquiring an additional 1,719 shares in the last quarter. Finally, Sigma Planning Corp grew its position in shares of Liquidia by 3.4% during the 4th quarter. Sigma Planning Corp now owns 65,210 shares of the company's stock valued at $767,000 after acquiring an additional 2,115 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Liquidia

In related news, insider Rajeev Saggar sold 2,445 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the transaction, the insider now directly owns 267,943 shares in the company, valued at $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Michael Kaseta sold 23,370 shares of the company's stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,245 shares of company stock worth $843,326. Company insiders own 30.10% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).